Sarepta Pauses Elevidys Shipments After Three Patient Deaths Linked to Gene Therapy

On July 22, Sarepta Therapeutics announced it would pause all shipments of Elevidys in the US, its gene therapy for Duchenne muscular dystrophy (DMD). The decision follows an official FDA request and the reported deaths of three patients, two of whom were treated with Elevidys, and one who received a similar investigational therapy in a clinical trial. All three cases involved acute liver failure. 

What happened? 

Elevidys was approved by the FDA in 2023 under the accelerated approval pathway for use in ambulatory children with DMD—a rare, progressive, and ultimately fatal genetic disorder. The approval was granted based on biomarker data showing increased production of micro-dystrophin, rather than clear clinical benefit in motor function. Despite the limited efficacy data, the urgency of the disease and strong advocacy from patient groups helped push the therapy to market. 

In March and June 2025, two teenage boys who had received Elevidys died from liver failure. Both had advanced-stage DMD and were no longer ambulatory. In response, Sarepta voluntarily paused shipments of the drug for non-ambulatory patients but continued offering it to ambulatory patients, arguing that its internal safety monitoring revealed no new risks in that population. 

However, in early July, a third death was disclosed: a 51-year-old man with limb-girdle muscular dystrophy (LGMD) died after receiving SRP-9004, another AAV-based investigational gene therapy developed by Sarepta. The shared vector platform between SRP-9004 and Elevidys raised further concerns. 

A regulatory standoff 

On July 18, the FDA formally requested that Sarepta pause all Elevidys shipments to reassess safety data and update the product label. Sarepta initially refused, citing confidence in its safety data and maintaining that the therapy remained appropriate for ambulatory patients. 

This response marked a rare and highly visible standoff between a biotech company and a federal regulator—especially notable given the stakes involved: a therapy for children with a fatal disease, and a platform technology with wide-reaching implications for gene therapy as a field. 

Adding to the pressure, Children’s Hospital Los Angeles—one of the largest Elevidys treatment centers—independently paused infusions, citing patient safety concerns. 

Sarepta reverses course 

On July 22, Sarepta announced it would fully comply with the FDA’s request and pause all US distribution of Elevidys. The company emphasized that the pause was voluntary and would allow time to: 

• Respond to FDA inquiries 

• Update the product label, including a black box warning for liver toxicity 

• Finalize a revised risk management plan in collaboration with the agency 

Additionally, the FDA has placed clinical holds on Sarepta’s LGMD trials and revoked the company’s platform technology designation, a move that could impact future development efforts for AAV-based gene therapies. 

Looking ahead 

While Sarepta describes the suspension of Elevidys as temporary, no timeline has been provided. For patients with Duchenne muscular dystrophy—many of whom face irreversible disease progression—the wait is not just painful, it’s perilous. 

This moment has laid bare the double-edged nature of accelerated innovation. When approvals are granted based on surrogate endpoints, the responsibility doesn’t end—it intensifies. Post-market vigilance becomes a moral imperative, not just a regulatory checkbox. 

The deaths linked to AAV-based therapies have forced the industry to confront a hard truth: when lives are at stake, delay is dangerous—but denial is fatal. 

Elevidys may still hold promise. Gene therapy will continue to evolve. But trust—among regulators, patients, and the public—is not granted indefinitely. It must be continually earned, especially when the science stumbles. 

The defining moments of this field won’t just come from the therapies we launch. They’ll come from how we lead when things go wrong. That is the real test of biotech’s maturity. 

Because breakthroughs don’t just require courage to move forward. They require the wisdom to stop—when the risk outweighs the rush. 

Update (based on Sarepta’s July 28, 2025 press release): Just days after the full suspension of Elevidys, Sarepta has announced that the FDA has completed its review and recommended that shipments resume for ambulatory DMD patients. The agency found no link between Elevidys and the death of an 8-year-old patient in Brazil, which had contributed to the initial pause. Sarepta will now restart shipments immediately for eligible patients, while discussions with the FDA continue regarding updated safety labeling and risk mitigation for non-ambulatory patients, who remain on hold. This rapid reversal underscores the urgency of access, the weight of safety oversight, and the value of transparent collaboration between regulators and innovators.